WFDC Protein: A Promising Diagnosis Biomarker of Ovarian Cancer

Overview

Journal J Cancer

Specialty Oncology

Date 2021 Aug 18

PMID 34405003

Citations 8

Authors

Chen Zhang

Haoyue Hu

Xiaoyan Wang

Yajuan Zhu

Ming Jiang

Affiliations

Soon will be listed here.

Abstract

An initial diagnosis of cancer is usually based on symptoms, abnormal physical examination and imaging tests. Ovarian cancer is difficult to be diagnosed timely due to the nonspecific symptoms, thus resulting in the high-risk mortality. Despite of the various diagnostic methods, there is still no reliable diagnostic test. Clinically, carbohydrate antigen 125(CA125) is widely recognized as a diagnosis biomarker of ovary cancer. However, CA125 is not sensitive to detect the ovary cancer at the early stage. It is essential to explore other potential biomarkers. Human epididymis protein 4 (HE4) in the whey/four-disulfide core (WFDC) proteins family shows satisfactory sensitivity in the early diagnosis of ovary cancer. In this present review, we summarized the important effects of WFDC family proteins on the proliferation, apoptosis and migration of ovary cancer and intended to provide more evidence to explore the possibility of WFDC protein as a diagnosis biomarker.

Citing Articles

The NF-κB-HE4 axis: A novel regulator of HE4 secretion in ovarian cancer.

Kim K, Khazan N, McDowell J, Snyder C, Miller J, Singh R PLoS One. 2024; 19(12):e0314564.

PMID: 39621651 PMC: 11611113. DOI: 10.1371/journal.pone.0314564.

The chromatin landscape of high-grade serous ovarian cancer metastasis identifies regulatory drivers in post-chemotherapy residual tumour cells.

Croft W, Pounds R, Jeevan D, Singh K, Balega J, Sundar S Commun Biol. 2024; 7(1):1211.

PMID: 39341888 PMC: 11438996. DOI: 10.1038/s42003-024-06909-9.

Versatile whey acidic protein four-disulfide core domain proteins: biology and role in diseases.

Wen Y, Jiang N, Wang Z, Xiao Y Front Cell Dev Biol. 2024; 12:1459129.

PMID: 39296934 PMC: 11408880. DOI: 10.3389/fcell.2024.1459129.

Knockdown of HE4 suppresses tumor growth and invasiveness in lung adenocarcinoma through regulation of EGFR signaling.

Zhang Y, Yang W, Han X, Qiao Y, Wang H, Chen T Oncol Res. 2024; 32(6):1119-1128.

PMID: 38827327 PMC: 11136691. DOI: 10.32604/or.2024.045025.

Human epididymis protein 4, a novel potential biomarker for diagnostic and prognosis monitoring of lung cancer.

Zhang T, Chu L, Tan W, Ye C, Dong H Clin Respir J. 2024; 18(5):e13774.

PMID: 38742362 PMC: 11091784. DOI: 10.1111/crj.13774.

References

Liao J, Yip Y, Swisher E, Agnew K, Hellstrom K, Hellstrom I . Detection of the HE4 protein in urine as a biomarker for ovarian neoplasms: Clinical correlates. Gynecol Oncol. 2015; 137(3):430-5. PMC: 4447602. DOI: 10.1016/j.ygyno.2015.03.044. View

Caruso J, Karakas C, Zhang J, Yi M, Albarracin C, Sahin A . Elafin is downregulated during breast and ovarian tumorigenesis but its residual expression predicts recurrence. Breast Cancer Res. 2015; 16(6):3417. PMC: 4326485. DOI: 10.1186/s13058-014-0497-4. View

Lee Y, Albig A, Regner M, Schiemann B, Schiemann W . Fibulin-5 initiates epithelial-mesenchymal transition (EMT) and enhances EMT induced by TGF-beta in mammary epithelial cells via a MMP-dependent mechanism. Carcinogenesis. 2008; 29(12):2243-51. PMC: 2621102. DOI: 10.1093/carcin/bgn199. View

Ribeiro J, Gaudet H, Khan M, Schorl C, James N, Oliver M . Human Epididymis Protein 4 Promotes Events Associated with Metastatic Ovarian Cancer Regulation of the Extracelluar Matrix. Front Oncol. 2018; 7:332. PMC: 5786890. DOI: 10.3389/fonc.2017.00332. View

Yuan Q, Song J, Yang W, Wang H, Huo Q, Yang J . The effect of CA125 on metastasis of ovarian cancer: old marker new function. Oncotarget. 2017; 8(30):50015-50022. PMC: 5564824. DOI: 10.18632/oncotarget.18388. View

Hamed E, Ahmed H, Sedeek O, Mohammed A, Abd-Alla A, Abdel Ghaffar H . Significance of HE4 estimation in comparison with CA125 in diagnosis of ovarian cancer and assessment of treatment response. Diagn Pathol. 2013; 8:11. PMC: 3621278. DOI: 10.1186/1746-1596-8-11. View

Kim B, Park Y, Kim B, Ahn H, Lee K, Chung J . Diagnostic performance of CA 125, HE4, and risk of Ovarian Malignancy Algorithm for ovarian cancer. J Clin Lab Anal. 2018; 33(1):e22624. PMC: 6430343. DOI: 10.1002/jcla.22624. View

Zhang L, Chen Y, Wang K . Comparison of CA125, HE4, and ROMA index for ovarian cancer diagnosis. Curr Probl Cancer. 2018; 43(2):135-144. DOI: 10.1016/j.currproblcancer.2018.06.001. View

Small D, Doherty D, Dougan C, Weldon S, Taggart C . The role of whey acidic protein four-disulfide-core proteins in respiratory health and disease. Biol Chem. 2016; 398(4):425-440. DOI: 10.1515/hsz-2016-0262. View

10.

Chen Y, Huang L, Wang S, Li J, Li M, Wu Y . contributes to epithelial-mesenchymal transition (EMT) by activating AKT signaling pathway and regulating MMP-2 expression. Cancer Manag Res. 2019; 11:2415-2424. PMC: 6497977. DOI: 10.2147/CMAR.S192950. View

11.

Deng L, Gao Y, Li X, Cai M, Wang H, Zhuang H . Expression and clinical significance of annexin A2 and human epididymis protein 4 in endometrial carcinoma. J Exp Clin Cancer Res. 2015; 34:96. PMC: 4567805. DOI: 10.1186/s13046-015-0208-8. View

12.

Goossens N, Nakagawa S, Sun X, Hoshida Y . Cancer biomarker discovery and validation. Transl Cancer Res. 2015; 4(3):256-269. PMC: 4511498. DOI: 10.3978/j.issn.2218-676X.2015.06.04. View

13.

Zhu L, Zhuang H, Wang H, Tan M, Schwab C, Deng L . Overexpression of HE4 (human epididymis protein 4) enhances proliferation, invasion and metastasis of ovarian cancer. Oncotarget. 2015; 7(1):729-44. PMC: 4808029. DOI: 10.18632/oncotarget.6327. View

14.

Chen Y, Mu X, Wang S, Zhao L, Wu Y, Li J . WAP four-disulfide core domain protein 2 mediates the proliferation of human ovarian cancer cells through the regulation of growth- and apoptosis-associated genes. Oncol Rep. 2012; 29(1):288-96. DOI: 10.3892/or.2012.2114. View

15.

Chen F, Shen J, Wang J, Cai P, Huang Y . Clinical analysis of four serum tumor markers in 458 patients with ovarian tumors: diagnostic value of the combined use of HE4, CA125, CA19-9, and CEA in ovarian tumors. Cancer Manag Res. 2018; 10:1313-1318. PMC: 5968799. DOI: 10.2147/CMAR.S155693. View

16.

Arechavaleta-Velasco F, Perez-Juarez C, Gerton G, Diaz-Cueto L . Progranulin and its biological effects in cancer. Med Oncol. 2017; 34(12):194. PMC: 5810362. DOI: 10.1007/s12032-017-1054-7. View

17.

Zhuang H, Tan M, Liu J, Li X, Gao J, Hu Z . The expression of annexin II and Lewis y antigen in ovarian epithelial tumors and the correlation between them. Tumour Biol. 2014; 36(4):2343-9. DOI: 10.1007/s13277-014-2841-9. View

18.

Zhao J, Guan J . Signal transduction by focal adhesion kinase in cancer. Cancer Metastasis Rev. 2009; 28(1-2):35-49. DOI: 10.1007/s10555-008-9165-4. View

19.

Lycke M, Kristjansdottir B, Sundfeldt K . A multicenter clinical trial validating the performance of HE4, CA125, risk of ovarian malignancy algorithm and risk of malignancy index. Gynecol Oncol. 2018; 151(1):159-165. DOI: 10.1016/j.ygyno.2018.08.025. View

20.

Urban N, McIntosh M, Andersen M, Karlan B . Ovarian cancer screening. Hematol Oncol Clin North Am. 2003; 17(4):989-1005, ix. DOI: 10.1016/s0889-8588(03)00063-7. View